cardiovascular

News
heart-840x470

Praluent approved to reduce CV risk in Europe

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan

News
Novartis licenses lipoprotein-lowering CVD drug

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

Views & Analysis
Pharma artificial intelligence

The future of stroke treatment

Stroke is a major cause of disability and death worldwide and the third most common cause of death in developed countries. Nearly six million people die from stroke every year and another five million are left permanently disabled.